Skip to main content
Premium Trial:

Request an Annual Quote

TM Bioscience, Biochip Maker Collaborate

Premium

TORONTO--TM Bioscience, which has developed five proprietary DNA product platforms--biochips, therapeutics, diagnostics, gene expression, and genomic analysis--signed a collaborative agreement with a manufacturer of biochips coving the application of TM's normalization of hybridization technology to biochips. TM's platforms are based on its discovery of a second encoding in DNA that governs DNA interactions within itself and with other molecules. Applied to biochips, the company's normalization technology provides that all sequences of DNA, independent of "GC" content, hybridize to a probe array with equal efficiency, thereby improving the quality of biochip output data.

Under the terms of the agreement, during an initial proof-of-concept stage TM must demonstrate the efficacy of its normalization technology to the satisfaction of the manufacturer, after which the agreement provides for payment to TM of fees and milestones up to $1 million, and for payments of royalties.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.